Business Context and Reporting Period
This Form 8-K Current Report was filed by Reactive Medical Inc. (also referenced as Artelo Biosciences, Inc. in metadata) on April 7, 2017, covering events occurring between March 22, 2017, and April 3, 2017. The company is focused on developing plant and synthetic-derived cannabinoid therapeutics for human clinical trials.
Key Financial Metrics
This filing does not contain standard financial statements, revenue, profit, cash flow, or debt metrics. The only financial data disclosed relates to specific transactional agreements:
- Consultancy Fees: Dr. Saoirse O'Sullivan to be compensated at £1,600 per calendar month for one day of work per week, with additional fees of £200 per half-day worked beyond the base commitment.
- Executive Compensation: Gregory D. Gorgas is eligible for an annual base salary of $250,000 and a target bonus of 50% of base salary, contingent upon the company securing funding exceeding $5,000,000.
- Equity Transaction: The company sold 1,760,000 shares of common stock to Mr. Gorgas for an aggregate purchase price of $1,760 ($0.001 per share).
Material Changes
The filing reports significant changes in corporate leadership and capital structure:
- Executive Departure and Appointment: On April 3, 2017, Peter O'Brien resigned from his roles as President, CEO, CFO, Secretary, and Treasurer to become Senior Vice President - European Operations. Gregory D. Gorgas was appointed to all former executive roles (President, CEO, CFO, Secretary, Treasurer) and added to the Board of Directors.
- Board Composition: The Board of Directors was increased to two members, consisting of Gregory Gorgas and Peter O'Brien.
- Unregistered Securities Sale: The company issued 1,760,000 shares to Mr. Gorgas under a Securities Purchase Agreement, relying on exemptions from registration requirements.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The company intends to use proceeds from the share sale for general working purposes. The appointment of Mr. Gorgas is driven by his experience in biotechnology financing and commercialization, with the goal of advancing the company's technology and intellectual property.
Contingencies and Risks:
- Funding Contingency: Mr. Gorgas's salary and bonus are conditional on the company attaining funding (debt or equity) in excess of $5,000,000.
- Share Repurchase Obligations: The Securities Purchase Agreement includes a clawback provision. If Mr. Gorgas's employment is terminated before the four-year anniversary, he must sell back a percentage of shares (ranging from 100% to 25%) to the company at the original purchase price.
- At-Will Employment: Mr. Gorgas's employment is at-will and can be terminated by either party with 30 days' notice.
Investor Verification Checklist
- Verify the company's current cash position and ability to meet the $5,000,000 funding threshold required to activate the CEO's salary.
- Confirm the dilution impact of the 1,760,000 shares issued to the CEO and any future equity issuances.
- Review the full text of the Consultancy Agreement (Exhibit 10.1) and Employment Agreement (Exhibit 10.2) for additional terms not summarized in the filing.
- Assess the strategic fit of the new leadership team given the transition from Peter O'Brien to Gregory Gorgas.